A study published this week in the July/August edition of the Parenteral Drug Association’s PDA Journal documents research that showed that in vitro test results for more than 100 biopharmaceutical products from eight major drug companies demonstrated no non-thermal effect by radio frequency radiation.
What does this mean? The research conducted by researchers at The University of South Florida, Blood Center of Wisconsin, Abbott, Georgia Institute of Technology and the Madison RFID Lab at the University of Wisconsin documents that using RFID in conjunction with biologics is safe. The thermal effects of RFID on biologics have been well understood (no impact) but there had, to this point, been limited research on the non-thermal effects (RF radiation) of RFID on product integrity.
Why is this important? Pending ePedigree laws in California (going into effect in 2015 and ultimately impacting the entire industry) are likely to require a combination of RFID and 2D barcoding systems. Some had questioned whether or not RFID was safe to use for these types of applications but this report (available to PDA members on the PDA website) demonstrates RFID’s safety, enabling technology companies, pharmaceutical manufacturers, shippers, 3PLs and health care providers to move forward more aggressively on developing solutions for ePedigree and documenting the safe and authentic shipments of biopharmaceutical products. But, RFID can add even more value. Temperature sensor RFID tags, beyond providing the ability to document track and trace records for ePedigree can also be used to monitor and manage the temperature (and related safety and efficacy) of drugs as they move through the supply chain to reduce waste and improve cold chain operations.
You can learn more about Intelleflex solutions for pharmaceuticals here.
Senior Director of Marketing